Azeliragon

Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) [1]. Azeliragon also can cross the blood-brain barrier (BBB) [2].

Product Specifications

CAS Number

[603148-36-3]

Product Name Alternative

TTP488; PF-04494700

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Amyloid-β

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Azeliragon.html

Purity

99.75

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(C=C1)OC2=CC=C(C=C2)N3C(CCCC)=NC(C(C=C4)=CC=C4OCCCN(CC)CC)=C3

Molecular Formula

C32H38ClN3O2

Molecular Weight

532.12

Precautions

H302, H315, H319, H335

References & Citations

[1]Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8 (4) :426-435.|[2]Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE) : A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60 (17) :7213-7232.|[3]Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181 (6) :4272-8.